Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - ethinylestradiol betadex clathrate - eq. ethinylestradiol 0,02 mg; drospirenone 3 mg - film-coated tablet - 0,02 mg - 3 mg - drospirenone 3 mg; ethinylestradiol betadex clathrate - drospirenone and ethinylestradiol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - ethinylestradiol betadex clathrate - eq. ethinylestradiol 0,02 mg (light pink tablet); drospirenone 3 mg (light pink tablet); placebo (white tablet) - film-coated tablet - 0,02 mg - 3 mg - drospirenone 3 mg; ethinylestradiol betadex clathrate; placebo - drospirenone and ethinylestradiol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - ethinylestradiol betadex clathrate - eq. ethinylestradiol 0,02 mg; drospirenone 3 mg - film-coated tablet - 0,02 mg - 3 mg - ethinylestradiol betadex clathrate; drospirenone 3 mg - drospirenone and ethinylestradiol

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - warfarin sodium clathrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - warfarin sodium clathrate, quantity: 5.543 mg (equivalent: warfarin sodium, qty 5 mg) - tablet - excipient ingredients: magnesium stearate; maize starch; lactose monohydrate; microcrystalline cellulose; brilliant blue fcf aluminium lake; quinoline yellow aluminium lake - warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism.,warfarin is indicated for the prophylaxis and\or treatment of the thromboembolic complications associated with atrial fibrillation.,warfarin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (e.g. previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart.,warfarin is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - warfarin sodium clathrate, quantity: 1.109 mg (equivalent: warfarin sodium, qty 1 mg) - tablet - excipient ingredients: maize starch; lactose monohydrate; microcrystalline cellulose; magnesium stearate; sunset yellow fcf; brilliant blue fcf aluminium lake; allura red ac aluminium lake - warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism.,warfarin is indicated for the prophylaxis and\or treatment of the thromboembolic complications associated with atrial fibrillation.,warfarin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (e.g. previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart.,warfarin is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - warfarin sodium clathrate, quantity: 2.217 mg (equivalent: warfarin sodium, qty 2 mg) - tablet - excipient ingredients: magnesium stearate; maize starch; lactose monohydrate; microcrystalline cellulose; colour - warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism.,warfarin is indicated for the prophylaxis and\or treatment of the thromboembolic complications associated with atrial fibrillation.,warfarin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (e.g. previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart.,warfarin is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - warfarin sodium clathrate, quantity: 1.109 mg (equivalent: warfarin sodium, qty 1 mg) - tablet - excipient ingredients: maize starch; lactose monohydrate; microcrystalline cellulose; magnesium stearate; sunset yellow fcf; brilliant blue fcf aluminium lake; allura red ac aluminium lake - warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism.,warfarin is indicated for the prophylaxis and\or treatment of the thromboembolic complications associated with atrial fibrillation.,warfarin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (e.g. previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart.,warfarin is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - warfarin sodium clathrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - warfarin sodium clathrate, quantity: 1.109 mg (equivalent: warfarin sodium, qty 1 mg) - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; maize starch; sunset yellow fcf; brilliant blue fcf aluminium lake; allura red ac aluminium lake - warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism.,warfarin is indicated for the prophylaxis and\or treatment of the thromboembolic complications associated with atrial fibrillation.,warfarin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (e.g. previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart.,warfarin is indicated for use as an adjunct in the treatment of coronary occlusion.